FDA panel backs new Alzheimer’s drug, despite risks and uncertainties
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
A new Alzheimer's drug has received backing from an FDA panel. The decision comes despite concerns over the drug's risks and uncertainties. The panel's endorsement suggests the drug may move forward, but its ultimate approval and impact are still unclear.